Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3

Masahiro Hiasa1, Tatsuo Okui1, Yohance M Allette2

  • 1Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, Indiana.

Cancer Research
|March 4, 2017
PubMed

Insights

Multiple myeloma causes severe bone pain by creating an acidic bone environment. Targeting acid-sensing nerves and this acidity offers a new strategy for pain relief.

Area of Science:

  • Oncology
  • Pain Research
  • Neuroscience

Background:

  • Multiple myeloma patients often suffer from severe, undertreated bone pain (MMBP).
  • The underlying mechanisms of MMBP remain poorly understood.
  • Existing treatments, like zoledronic acid, are not always effective.

Purpose of the Study:

  • To investigate the mechanisms of MMBP using a mouse xenograft model.
  • To explore the role of bone microenvironment acidity and sensory nerves in MMBP.
  • To evaluate potential therapeutic targets for MMBP.

Main Methods:

  • Utilized an intratibial mouse xenograft model with JJN3 human multiple myeloma cells.
  • Measured sensory nerve sprouting (CGRP+), neuronal excitation markers (pERK1/2, pCREB), and bone microenvironment pH.
  • Administered V-ATPase inhibitor (bafilomycin A1), ASIC3 antagonist (APETx2), and zoledronic acid.

Main Results:

  • The model showed increased CGRP+ nerve sprouting and neuronal excitation markers associated with MMBP.
  • JJN3 cells induced an acidic bone microenvironment via V-ATPase.
  • Inhibition of V-ATPase or ASIC3, individually or combined, significantly reduced MMBP.

Conclusions:

  • Osteoclasts and multiple myeloma cells collaborate to create an acidic bone environment, activating ASIC3+ sensory neurons and causing MMBP.
  • Targeting the acidic bone microenvironment and ASIC3+ neurons presents a promising therapeutic strategy for MMBP.
  • Combination therapy targeting V-ATPase and ASIC3, or V-ATPase and osteoclasts, effectively ameliorated MMBP.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K